Camargo Pharmaceutical Services recently completed an extensive IT system update
Camargo Pharmaceutical Services
recently completed an extensive IT system update to offer its clients improved data availability, security, storage and redundancy. The new system is an important investment to Camargo’s infrastructure, allowing the full-service development partner to add value for its clients.
With these improvements, Camargo provides each of its national and international clients with an individual website including large-scale data storage availability, document management with version control, a superior level of security with minimal interruptions and 24/7 rapid access. The system also includes data retention and preservation for at least 20 years — exceeding the FDA’s and global regulatory agencies’ minimum data preservation requirements.
“Implementing enhanced data access and storage capacity are examples of the strides Camargo is making to broaden our service line, support our clients from concept through commercialization and grow our client base internationally,” said Jim Beach, chief operating officer for Camargo. “Data and its preservation are the lifeblood of product development programs and this new system supports our critical role as stewards of our clients’ data.”
To learn more about Camargo’s service offerings, visit
camargopharma.com
.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Phase III PROMINENT Trial Initiated to Evaluate Felzartamab for Primary Membranous Nephropathy
June 30th 2025The global Phase III PROMINENT trial has begun dosing patients to evaluate felzartamab in treating primary membranous nephropathy, a serious autoimmune kidney disorder with no FDA-approved therapies.